Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis
Ischemic Stroke, Vertebral Artery Stenosis
About this trial
This is an interventional treatment trial for Ischemic Stroke
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years old, gender is not limited; Patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems; Patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form. Exclusion Criteria: Unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery; With an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery; Gastrointestinal disease with active bleeding; Previous myocardial infarction or large-scale cerebral infarction within 2 weeks; Known contraindications to heparin, rapamycin, anesthesia, and contrast agents; Life expectancy less than 12 months; the investigator judged patients to be unsuitable for participation in this study.
Sites / Locations
- Nanfang Hospital of Southern Medical UniversityRecruiting
Arms of the Study
Arm 1
Experimental
Patients with vertebral atherosclerotic stenosis requiring stent implantation
Referring to "the 2015 Chinese Guidelines for Endovascular Interventional Treatment of Ischemic Cerebrovascular Disease", "the 2015 Symptomatic Atherosclerotic Sclerotic vertebral artery initiation stenosis: Chinese expert consensus" and "Subclavian/extracranial vertebral artery stenosis: Chinese expert consensus" in 2019 and other guidelines and expert consensus for the diagnosis of symptomatic vertebral artery atherosclerotic stenosis ≥ 50% and non-symptomatic vertebral artery atherosclerotic stenosis ≥ 70% in patients.